Sarcoidosis Research into the Cause of Multi organ Disease and Clinical Strategies for Therapy (R01) | Apply Online

Opportunity Summary:

The NIH Funding Opportunity Announcement PA-07-136, titled "Sarcoidosis Research into the Cause of Multi-organ Disease and Clinical Strategies for Therapy (R01)," is meant to drive new, well-designed research into why sarcoidosis happens and how it can be managed more effectively. Sarcoidosis is described here as a human disease marked by granulomatous inflammation and it can affect many organs, creating a wide range of clinical outcomes and long-term burdens for patients and families. The central aim of the opportunity is to accelerate progress toward identifying the underlying cause or causes of sarcoidosis, while also improving diagnosis, prevention, and treatment approaches that can reduce both medical harm and everyday life impacts.

A major emphasis of the announcement is etiologic discovery, not only in the sense of pinpointing a direct trigger, but also in understanding predisposing factors that make certain people susceptible or put them at higher risk. The FOA explicitly highlights modern "omics" and related discovery approaches as relevant tools, including genomics, proteomics, metabolomics, lipidomics, and glycomics. In practice, that means applicants are encouraged to investigate host characteristics and molecular signatures that might explain why sarcoidosis begins, why it persists in some people, and why it resolves in others. The program is also interested in research that clarifies phenotypes, meaning the observable patterns of disease across individuals, and how those phenotypes relate to underlying biology. The long-term logic is straightforward: if researchers can define causes and susceptible host traits more clearly, it becomes more realistic to develop prevention strategies, detect disease earlier, and design therapies that blunt damaging immune responses before they lead to irreversible organ injury.

The FOA also invites research focused on immunology and multi-organ involvement, especially work that explains how sarcoidosis disrupts both innate and adaptive immune systems and how those immune disturbances translate into inflammation across the body. While the respiratory tract is a key focus because pulmonary sarcoidosis is common, the program specifically calls attention to other frequently involved organs and highlights "critical involvement" sites such as the heart, eyes, liver, and the neurologic system. This reflects the reality that sarcoidosis can be life-altering or life-threatening when it affects certain organs, and that research targeting these manifestations could meaningfully improve outcomes.

Beyond biology and clinical endpoints, the announcement signals interest in the broader lived burden of sarcoidosis, including biobehavioral and psychosocial factors affecting individuals, families, and communities. Applicants are encouraged to consider the social and psychological dimensions of the disease, including risk reduction strategies, psychological coping, and the management of complications or side effects from treatment. There is also a clear preference for interventions that are cost-effective and that reduce burden not just in terms of symptoms, but also in terms of healthcare use, long-term disability, caregiver strain, and community impact. In addition, the FOA encourages the development or improvement of methodologies and instruments that can measure disease burden more accurately, which can include better clinical metrics, patient-reported outcomes, or tools that capture multi-organ disease severity and quality-of-life effects.

In terms of funding structure, the opportunity uses the NIH R01 mechanism, meaning it supports investigator-initiated research projects that can span basic science, translational work, and clinical research, as long as the proposed aims fit the program priorities. Award size and project duration are not fixed; they are expected to vary depending on the scientific scope, proposed timeline, and justified budget needs. The NIH notes that the number of awards and the total amount funded will ultimately depend on the quantity and quality of applications received, along with program priorities and available funds.

Eligibility is broad across many domestic organization types, including higher education institutions (public and private), nonprofits (including those with and without 501(c)(3) status), for-profit organizations (with small businesses explicitly listed), state, county, city or township governments, special district governments, independent school districts, public housing authorities/Indian housing authorities, and tribal governments and tribal organizations (including federally recognized tribal governments). Faith-based and community-based organizations are also allowed to apply, and eligible federal government agencies may apply as well. A key limitation is that foreign institutions are not eligible to apply under this FOA. The announcement lists multiple receipt dates rather than one single deadline, directing applicants to the full announcement for the specific submission schedule and details.

Administratively, the opportunity is issued by the National Institutes of Health and is categorized as a discretionary grant in health-related research and education areas. The FOA is associated with several CFDA numbers that reflect the cross-cutting nature of sarcoidosis research, spanning nursing research, lung diseases, arthritis/musculoskeletal/skin research, neuroscience and neurological disorders, microbiology and infectious diseases, and vision research. It does not require cost sharing or matching. The full announcement and official requirements are available through the NIH grants guide link provided in the source material.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01)

Previous opportunity: Integrating Lung Genetics and Genomics in Human Populations (R01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 07 136

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 07 136) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 136", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.